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1. Introduction 
Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and 
characterized by progressive development, high postsurgical recurrence and extremely poor 
prognosis [1–3]. The dismal outcome has been attributed to the highly vascular nature of 
HCC, which increases the propensity to spread and invade into neighboring or distant sites 
[4, 5]. Therefore, it is considered an urgent task to identify key prognostic factors of HCC 
and to elucidate the mechanisms of disease progression. 
HCC is usually present in inflamed fibrotic and/or cirrhotic liver with extensive leukocyte 
infiltration [6, 7]. Thus, the immune status at different tumor sites can largely influence the 
biological behavior of HCC [6, 8, 9]. Several recent studies have shown that high infiltration 
of intratumoral regulatory T cells is associated with reduced survival and increased 
invasiveness in HCC [10, 11]. These findings are in accordance with the general view that 
the tumor microenvironment induces tolerance [12–14]. However, there is substantial 
evidence that the inflammatory response associated with cancers can also promote HCC 
progression by stimulating angiogenesis and tissue remodeling [6, 15, 16]. These findings 
strongly indicate that, besides inducing immune tolerance, HCC may also reroute the pro-
inflammatory immune response into a tumor-promoting direction. 
Macrophages (Mφs) constitute a major component of the leukocyte infiltrate in tumors. 
These cells are derived from circulating monocytes, and, in response to environmental 
signals, they acquire special phenotypic characteristics with diverse functions [17–19]. 
Recent studies have found that tumor environments co-opt the normal development of Mφs 
to dynamically activate the recruited monocytes in different niches of HCC. The malignant 
cells can thereby avoid initiation of potentially dangerous Mφ functions and create favorable 
conditions for tumor progression [20, 21]. Notably, the density of activated monocytes in the 
peritumoral stroma is selectively associated with vascular invasion and poor prognosis in 
HCC patients, whereas the increased infiltration of suppressive Mφs in the cancer nests is 
only correlated with the reduced survival of patients [22]. Thus, immune functional data of 
activated monocytes/Mφs in distinct cancer environments are essential for understanding 
their roles and potential mechanisms in HCC immunopathogenesis. 
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In this chapter, we will summarize the current knowledge about the tumor immune 
microenvironment of HCC and the role of monocytes/Mφs in HCC progression, paying 
particular attention to the tissue micro-localization and phenotype of these cells. Additionally, 
we will describe the poly-directional communications between monocytes/Mφs and other 
stroma cells, including cytotoxic T cells, regulatory T cells, TH17/TC17 cells as well as 
neutrophils, and how activated monocytes in HCC repurpose the inflammatory response 
away from antitumor immunity and toward tissue remodeling and pro-angiogenic pathways. 
Finally, possible implications for the design of novel monocyte/Mφ-based immunotherapeutic 
strategies will be discussed. 
2. Immune microenvironments of human HCC 
After several decades of neglect, tumor microenvironments are once again an area of active 
research interest in cancer [23–25]. The biology of cancer cannot be understood simply by 
underlining the significance of the malignant cells but instead must encompass the 




Fig. 1. Infiltration patterns of immune cells in HCC samples. Paraffin-embedded HCC 
sections were stained with indicated antibodies. The micrographs show the stained 
peritumoral stroma (A) and cancer nest (B). 
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Human HCC microenvironments, composed of non-cancer cells and their stroma (Figure 1), 
are now recognized as a major factor influencing the disease progression [6, 21]. Although 
normal stromal environment is non-permissive for HCC progression, hepatoma cells can 
modulate adjacent stroma to generate a supportive microenvironment. This includes the 
ability to alter the ratios of effectors to regulatory T cells and to affect the functions of APCs 
and the expression of co-signaling molecules, which in turn creates an immunosuppressive 
network to promote tumor progression and immune evasion [10, 21, 26]. However, there is 
also emerging evidence that the pro-inflammatory response at the tumor stroma can be 
rerouted in a tumor-promoting direction [15, 16]. These observations suggest that different 
tumor microenvironments can create either immune suppression or activation at distinct 
sites to promote tumor progression. 
2.1 Immune responses against HCC 
In HCC, several lines of evidence have suggest a positive role of immune system, e.g., by 
controlling hepatoma growth [7, 27–29]. Indeed, data from clinical investigations have 
revealed that HCC patients with an increased intratumoral accumulation of cytotoxic CD8+ 
T lymphocytes had a superior 5-year survival rate and a prolonged recurrence-free survival 
after liver resection [11, 30]. In contrast, HCC-infiltrating CD4+ T lymphocytes exhibited a 
CD25highFoxp3+ phenotype that was a predictor of poor overall survival of patients, 
indicating distinct roles of different tumor-infiltrating lymphocyte subsets in HCC [10, 11]. 
The important role of CD8+ T cells in HCC control is further supported by studies in 
hepatoma-bearing mice; and interferon (IFN)-Ǆ, perforin and granzyme B produced by 
CD8+ T cells had been shown to be several major effector mechanisms for apoptosis of 
hepatoma cells [21, 31, 32]. 
Of note, the tumor-specific antigens (TSAs) in HCC patients are currently still under 
investigation. At present, several tumor-associated antigens (TAAs) of HCC have been 
identified, which has been recently introduced [7, 33]. In brief, several shared tumor 
antigens could also be recognized as antigens targeted by cytotoxic CD8+ T cells in HCC, 
e.g., human telomerase-reverse transcriptase (hTERT) or NY-ESO-1. Expression of these 
antigens has been reported for other malignancies as well. Other antigens are expressed 
specifically in HCC and are also recognized by cells of the immune system, e.g., ǂ-
fetoprotein (AFP) or Glypican-3. The latter two antigens belong to the family of oncofetal 
antigens that are expressed only during ontogenesis. Although the exact mechanisms 
underlying are not yet clear, re-expression of such antigens is often observed in HCC. Thus, 
further research is also required to determine the frequency, immunodominance and 
strength of the immune responses induced against different TAAs. 
Besides tumor-specific cytotoxic CD8+ T cells, the natural killer (NK) cells have also been 
implicated in a successful immune response against HCC, e.g., by direct lysis of malignant 
cells [34]. Indeed, an increased preoperative NK cell activity that related to the expression of 
perforin and granzyme B was correlated with prolonged recurrence-free survival in HCC 
patients [35]. Contrarily, the NK cell dysfunction was shown to predict the poor survival of 
HCC patients after resection [36]. Other studies also showed that the stimulation of antigen-
present cells (APCs) or natural killer T cells (NKT cells) can lead to an activation of NK cells 
and clearance of hepatoma cells in mice [37, 38]. 
Increased levels of B cells have been observed in several types of human tumor, and studies 
in mice indicate that, depending on microenvironment, tumor-infiltrating B cells are capable 
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of being pro- or anti-tumorigenic [39, 40]. The role of B cells in human HCC is unclear thus 
far. B cell-derived autoantibodies against several antigens have been described in mouse 
models of HCC as well as in HCC patients [41, 42]. Additional studies showed that 
monoclonal antibodies against Glypican-3 were able to induce antibody-dependent cellular 
cytotoxicity (ADCC) and thus lysis of human hepatoma cells in vitro and in mice [43]. 
However, the importance of ADCC and antibodies in general in the natural immune 
response against HCC has not been investigated so far. 
2.2 Immune responses promote HCC progression 
Although immune system can exhibit vigorous anti-hepatoma activities in vitro, HCC-
specific immune responses fail to control tumor progression in most patients. Clinical and 
experimental studies have demonstrated that the growth of HCC is closely associated with 
impaired differentiation and maturation of APCs, particularly Mφs and dendritic cells (DCs) 
[20, 44, 45]. Also, phenotypic and functional analyses of APCs from HCC patients have 
revealed that tumor cells or tumor-derived factors do favor differentiation of monocytes into 
tumor-associated Mφs (TAMs) [20] or tolerogenic semi-mature DCs (TDCs) [46]. Also, such 
abnormal development of APCs in the HCC microenvironment could intensely impact the 
infiltration and function of other immune cells in tumor in situ, which will be expounded in 
the 3rd section of this chapter.  
Suppression of immune responses by regulatory T (Treg) cells is one of the major 
mechanisms for the induction and maintenance of self-tolerance [12, 13]. Recent studies 
reported increased numbers of Treg cells in the peripheral blood and tumor-infiltrating 
lymphocytes (TILs) in patients with ovarian or liver cancers, which impaired cell-mediated 
immunity and promoted disease progression [10, 11, 47, 48]. Experimental depletion of Treg 
cells in several types of tumor-bearing mice could successfully improve tumor clearance and 
enhance the efficacy of immunotherapy [49, 50]. In parallel, depletion of CD4+CD25+ Treg 
cells could effectively enhance T-lymphocyte and NK-cell effector function in advanced 
stage HCC patients [51, 52]. These data together suggest that Treg cells may impair cell-
mediated immune responses to HCC. At present, the precise underlying mechanism by 
which Treg cells accumulate at the tumor site in HCC patients is also unknown. 
A direct role in HCC progression has also been shown for other cells of the immune system. 
For example, high infiltration of intratumoral neutrophils has been shown to predict a reduced 
recurrence-free survival time of HCC patients after liver resection [53]. Of note, neutrophils at 
the tumor edge induced angiogenesis progression and thus indirectly enhanced cancer growth 
[9]. This observation becomes especially intriguing in light of the finding that peritumoral 
neutrophils can be recruited by the pro-inflammatory cytokine interleukin (IL)-17. IL-17 is 
produced by T cells, termed TC17 or TH17, in the CD8+ or CD4+ T cell compartment in tumor 
environments, respectively [54, 55]. Indeed, IL-17-producing cells accumulate in tumors from 
patients with HCC and that their levels are positively correlated with microvessel density in 
tissues and poor survival in HCC patients [56]. It should be noted that, in several types of 
human cancer, high level of IL-17 in tumors in situ can predict improved survival of patients 
and associates with increased infiltration of cytotoxic CD8+ T cells [57, 58]. Therefore, a better 
understanding of the network of tumor immune environments might provide a novel strategy 
for the rational design of anticancer therapies. 
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3. Polarization of monocytes in HCC microenvironments 
APCs are critical for initiating and maintaining tumor-specific T-cell responses [21, 46]. DCs 
are considered the most effective APCs for primary immune responses [59]; Mφs markedly 
outnumber other APCs and represent an abundant population of APCs in solid tumors [60]. 
Monocytes can give rise to either DCs or Mφs in human tumors. In HCC patients, increased 
HLA-DR+ monocytes in liver are associated with metastatic phenotype [6]. Thus, 
polarization of monocytes in the cancer environments is essential for understanding their 
roles in HCC immunopathogenesis. 
3.1 Differentiation of monocyte-derived Mφs in HCC microenvironments 
Mφs are essential components of host defense and act as both APCs and effector cells [19]. 
Under the influence of local conditions, they acquire specialized phenotypic characteristics 
with diverse functional programs [16–18]. Mφs constitute a major component of the leukocyte 
infiltrate of tumors, and the TAMs are derived almost entirely from circulating blood 
monocytes [17–19]. Mφs in normal or inflamed tissues exhibit spontaneous antitumor activity, 
whereas TAMs are polarized M2 cells that suppress antitumor immunity and promote tumor 
progression [61]. Those findings agree with clinical studies showing that a high density of 
TAM is associated with poor prognosis in most solid tumors [22, 62]. Although the precise 
underlying mechanisms are not yet clear, it is generally assumed that the tumor 
microenvironment is critical determinants of the phenotype of local Mφs. Tumor-derived 
factors, including IL-10 and transforming growth factor (TGF)-ǃ, “educate” the newly 
recruited monocytes to take on a M2 phenotype and perform a protumoral role [63, 64]. In 
contrast, over-expression or local delivery of IL-12 can reestablish the antitumor activity of 
Mφs, and in that case a high density of TAMs is correlated with a marked reduction in tumor 
growth [65, 66]. Such opposing effects of Mφs on tumor progression indicate that selective 
modulation of Mφ polarization might serve as a novel strategy for cancer therapy. However, 
such an approach is hampered by the fact that the mechanisms by which tumor 
microenvironments educate Mφs to perform specific tasks have not been fully elucidated. 
In HCC patients, soluble factors derived from hepatoma cells, including extracellular matrix 
components hyaluronan fragments [20], effectively induced the formation of TAMs. 
Interestingly, kinetic analysis revealed 2 opposing functional stages in the TAM life cycle: 
monocytes are rapidly activated during a narrow time window, 4 to 16 hours after their first 
exposure to hepatoma cell culture supernatants, and afterward the same cells become 
exhausted and their production of cytokines is extinguished, with the exception of IL-10 [20, 
21]. Because TAMs are derived from blood monocytes, such sequential pre-activation and 
exhaustion of cells may reflect a novel immune-escape mechanism by which tumors 
dynamically regulate the functions of migrating monocytes at distinct tumoral sites. More 
precisely, this means that during their first exposure to the tumor microenvironment, the 
newly recruited monocytes may be transiently activated while they are approaching the 
stroma surrounding the tumor, with the aim of minimizing their potential to damage tumor 
cells. Thereafter, when these Mφs are in close proximity to the tumor cells, they become 
exhausted and thus fail to mount an effective antitumor immune response. This notion is 
supported by the observations in human HCC tissues, indicating that most CD68-positive 
cells are smaller and show high expression of HLA-DR in the peritumoral stromal region, 
whereas they exhibit a HLA-DRlowIL-10high phenotype in the cancer nest (Figure 3 in Ref. 20). 
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Of note, similar activation patterns of monocytes/Mφs were detected in ovarian and lung 
cancer [20, 67]. 
Monocytes/Mφs in the peritumoral stroma of HCC had an activated phenotype with 
increased expression of HLA-DR, CD80, and CD86 [6]. Data from in vivo observations 
showed that such tumor-activated monocytes also expressed significant level of B7-H1 (PD-
L1) [8, 21]; and autocrine TNF-ǂ and IL-10, but not IFN-Ǆ, released from activated 
monocytes, stimulated monocyte B7-H1 expression [21, 68]. Furthermore, in vitro study 
using recombinant TNF-ǂ and IL-10 indicated that IL-10 was essential for B7-H1 induction 
and that pro-inflammatory TNF-ǂ acted synergistically with anti-inflammatory IL-10 to 
enhance B7-H1 expression on monocytes. In addition, a positive correlation between IL-17-
producing cells and B7-H1-expressing Mφs was also observed in the peritumoral stroma of 
HCC tissues (Figure 1 in Ref. 8). Although culture supernatants derived from hepatoma 
cells also induced B7-H1 expression on monocytes, IL-17 additionally increased hepatoma-
mediated monocyte B7-H1 expression. Similar regulatory effect of IL-17 on APCs was also 
observed in hepatitis [69]. These findings reveal a fine-tuned collaborative action between 
different types of immune cells in the peritumoral stroma of HCC, which reroutes the 
monocyte inflammatory response into immunosuppression. 
TAMs in the cancer nests of HCC exhibited an exhausted suppressive phenotype; they are 
strongly impaired with regard to various functions related to inflammation [20, 21]. 
However, in contact with autologous T cells, these suppressive Mφs recuperate their 
capabilities to produce low level of IL-12 in tumors, and thereby activate T cells to produce 
IFN-Ǆ, which in turn leads to IDO expression in Mφs and ultimately impairs the antitumor T 
cell immunity (Zhao Q, et al. J Immunol. doi: 10.4049/jimmunol.1100164). These findings 
give important new insights into the collaborative action of tumor stroma cells that is 
exercised to counteract the normal development of Mφs in distinct HCC environments. 
3.2 Differentiation of monocyte-derived DCs in HCC microenvironments 
DCs are the most potent “professional” APCs, and they are responsible for integrating a 
variety of incoming signals and orchestrating the immune response [59]. Bidirectional 
interactions between DCs and T cells initiate either an immunogenic or a tolerogenic 
pathway, both of which play crucial roles in autoimmune diseases and tumor immunity [70, 
71]. It is generally assumed that these two contrasting functions of DCs are associated with 
the maturation stages of the cells: fully mature DCs (mDCs) are efficient activators of naive 
T cells, whereas immature DCs (iDCs) have been implicated for anergy induction. 
Furthermore, an intermediate stage of maturation was recently described in which the cells 
are referred to as semi-mature DCs [72]. These DCs expressed high levels of MHC class II 
and co-stimulatory molecules, even though they exhibited an IL-12lowIL-10high phenotype 
[73]. It was also observed that the semi-mature DCs can induce tolerance by generating 
regulatory T cells and/or T cell anergy [74]. 
In HCC patients, soluble factors derived from hepatoma cells drove human monocytes to 
become tolerogenic DCs (TDCs) that exhibited a semi-mature phenotype with a 2- to 5-fold 
increase in expression of CD83, CD86, and HLA-DR, and a distinctive IL-12lowIL-10high 
cytokine production profile [46]. Upon encountering T cells, the TDCs triggered rapid 
down-regulation of CD3ε and TCR-ǂ/ǃ and subsequent apoptosis in autologous T cells. 
www.intechopen.com
 
Immunobiology of Monocytes/Macrophages in Hepatocellular Carcinoma 
 
163 
Consistent with these results, accumulation of immunosuppressive DCs coincided with 
CD3ε down-regulation and T cell deletion in the cancer nests of human HCC tumors (Figure 
2 and 4 in Ref. 46). The impaired T cell function was mediated by factor(s) released by live 
TDCs after direct interaction with lymphocytes. Also, the TDC-induced effect on T cells was 
markedly reduced by blocking of NADPH oxidase but not by inhibition of arginase, 
inducible NO synthase (iNOS), indoleamine 2, 3-dioxygenase (IDO), or IFN-Ǆ. These 
observations indicate that tumor microenvironments educate DCs to adopt a semi-mature 
phenotype, which in turn aids tumor immune escape by causing defects in the CD3/TCR 
complex and deletion of T cells. In addition, besides triggering T cell apoptosis, hepatoma-
exposed DCs also play an important role in expanding intratumoral Treg cells [45]. 
4. Cross talks between monocytes/Mφs and other stroma cells in HCC 
tissues 
Tumor progression is now recognized as the product of evolving crosstalk between different 
cell types within the tumor and its stroma [23, 24]. HCC environments can alter the normal 
development of Mφs that is intended to trigger transient early activation of monocytes in 
the peritumoral region, which in turn induces formation of suppressive TAMs in the cancer 
nests [20, 21]. In this section, we will describe several recent findings about the cross talks 
between monocytes/Mφs and other stroma cells, paying particular attention to the tissue 
micro-localization and phenotype of these cells in HCC.  
4.1 Activated monocytes in the peritumoral stroma of HCC foster immune privilege 
and disease progression through B7-H1 
B7-H1 is a cell-surface glycoprotein belonging to the B7 family of co-signaling molecules 
with a profound regulatory effect on T cell responses [75]. Studies in mouse models have 
revealed that expression of B7-H1 helped dormant tumor cells to evade cytotoxic T cell 
responses [14]. In human HCC, B7-H1+ monocytes/Mφs and CD8+ T cells were both 
accumulated in the peritumoral stroma of HCC tissues, which suggests that these 
monocytes/Mφs promote tumor progression by impairing T cell immunity (Figure 1, 3-5 in 
Ref. 21). Supporting this hypothesis, a significantly larger portion of the tumor-infiltrating 
cytotoxic T cells was found to express the B7-H1 receptor PD-1 [8, 21, 68]. Moreover, HCC-
infiltrating T cells co-cultured with HCC-derived monocytes exhibited an impaired 
production of IFN-Ǆ, and blockade of B7-H1 by pre-incubation of tumor monocytes with the 
mAb MIH1 could markedly enhance the ability of tumor T cells to produce that cytokine. 
Consistent with these data, only PD-1+ cytotoxic T cells isolated from HCC tissues exhibited 
attenuated production of IFN-Ǆ, IL-2, and TNF-a as well as low cytotoxic potential [21]. 
These findings, together with regulatory mechanism of B7-H1 in monocytes/Mφs (Section 
2A), suggest that there is a fine-turned collaborative action between immune activation and 
immunosuppression in tumor microenvironments. Soluble factors derived from hepatoma 
cells [21], as well as IL-17 released by TH17 and TC17 [54, 55], can trigger transient 
activation of newly recruited monocytes in the peritumoral stroma area of HCC, and 
thereby induce the monocytes to produce significant amount of cytokines, including TNF-ǂ, 
IL-23, IL-1ǃ, and IL-10, which in turn leads to the expression of B7-H1 protein on their 
surface and ultimately impairs the antitumor T cell immunity. 
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4.2 Activated monocytes in the peritumoral stroma of HCC promote expansion of 
memory IL-17-producing T cells 
Although cancer patients exhibit a generalized immunosuppressive status, substantial 
evidence indicates that the inflammatory reaction at a tumor site can promote tumor growth 
and progression. HCC is usually derived from inflamed cirrhotic liver with extensive 
leukocyte infiltration. Recent study has shown that TH17 cells were highly enriched in HCC 
and their levels were positively correlated with micro-vessel density in tissues and poor 
survival in HCC patients [56]. In contrast to the classical TH17 cells that hardly express IFN-
Ǆ, almost half of the IL-17-producing CD4+ T cells we isolated from HCC tissues were able to 
simultaneously produce IFN-Ǆ, suggesting that the tumor microenvironment can 
profoundly determine the phenotype of such cells [54–56]. In addition, the IL-17-producing 
cells often predominantly accumulate in the peritumoral stroma rather than in the cancer 
nests of HCC [54, 55]. A significant correlation between the levels of CD68+ cells and IL-17+ 
lymphocytes was found in the peritumoral stroma of HCC (Figure 1 in Ref. 54). However, 
there was no such correlation in intratumoral tissue, suggesting that Mφs in different parts 
of HCC play disparate roles in IL-17-producing T cell expansion.  
Most of the CD68+ cells in the peritumoral stroma had a smaller volume and showed 
marked expression of HLA-DR, which implies that they were newly recruited and activated 
monocytes. In contrast, most Mφs in the cancer nests were negative for HLA-DR (Figure 2). 
Accordingly, hepatoma-activated monocytes were significantly superior to the suppressive 
tumor Mφs in inducing expansion of both TH17 (CD4+ IL-17-producing T cells) and TC17 
(CD8+ IL-17-producing T cells) cells from circulating memory T cells in vitro with 
phenotypic features similar to those isolated from HCC, and these monocytes secreted a set 
of key pro-inflammatory cytokines, including IL-1ǃ, IL-6, and IL-23, that triggered 
proliferation of functional TH17 cells. In addition, inhibition of monocytes/Mφs 
inflammation in liver markedly reduced the level of tumor-infiltrating IL-17+ cells and 
tumor growth in vivo [54]. Therefore, the pro-inflammatory IL-17-producing cells are  
 
Fig. 2. Distinct activation patterns of monocytes/Mφs in HCC samples. Adjacent sections 
of paraffin-embedded HCC samples were stained with an anti-CD68 (A) or anti-HLA-DR 
(B). The micrographs at higher magnification show the stained cancer nest (1), peritumoral 
stroma (2), and adjacent normal tissue (3). 
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generated and regulated by a fine-tuned collaborative action between different types of 
immune cells in distinct HCC microenvironments, and allow the inflammatory response of 
activated monocytes to be rerouted in a tumor-promoting direction. Selectively modulating 
the “context” of inflammatory response in tumors might provide a novel strategy for 
anticancer therapy. 
4.3 Peritumoral neutrophils link inflammatory response to disease progression by 
fostering angiogenesis in HCC 
Most monocytes/Mφs in the peritumoral stroma of HCC exhibit an activated phenotype 
that favors the generation of IL-17-producing cells in the same area, and their levels were 
correlated with disease progression in HCC patients [54]. Interestingly, another important 
myeloid cell population, namely tumor-associated neutrophils (TANs), was also enriched 
predominantly in the peritumoral stroma of HCC tissues, and their levels were well 
correlated with IL-17-producing cell density in the same area (Figure 2 in Ref. 9). Data from 
both clinical sample analysis and experimental studies showed that functional IL-17+ cells in 
the peritumoral stroma stimulated epithelial cells to produce CXC chemokines that induced 
neutrophil trafficking to tumors [9]. Thereafter, exposure of neutrophils to HCC 
environment resulted in sustained survival of cells [76]. The accumulated neutrophils in the 
peritumoral stroma were the major source of MMP-9, which in turn triggered the angiogenic 
switch at the adjacent invading edge [9]. These data, therefore, provide direct evidence that 
neutrophils play an important role in human tumor progression by serving as a link 
between the pro-inflammatory response and angiogenesis in the tumor milieu. This notion 
is supported by the findings that the density of neutrophils in the peritumoral stroma was 
correlated with advanced disease stages and could serve as an independent predictor of 
poor survival in HCC patients (Figure 1 in Ref. 9). Consistent with these results, tumor 
angiogenesis is often more active at the invading edge, which is close to the peritumoral 
stroma, than intratumoral areas. 
4.4 Activated CD69
+
 T cells foster immune privilege by regulating Mφ IDO expression 
in the cancer nest of HCC 
IDO is a rate-limiting enzyme for tryptophan catabolism. In humans and mice, IDO inhibits 
antigen-specific T cell proliferation in vitro and suppresses T cell responses to fetal 
alloantigens during murine pregnancy [71, 77, 78]. Expression of IDO is often induced or 
maintained by many inflammatory cytokines, of which IFN-Ǆ is the most potent [71]. In 
addition to being expressed in APCs, most human cancers also express high levels of IDO 
protein which correlates with poor prognosis in some cases [78]. In contrast, low or rare IDO 
expression is observed in most mouse and human tumor-cell lines, possibly due to the lack of 
a complete cancer microenvironment in cell lines in vitro [78, 79]. At present, little is known 
about the regulating mechanisms of IDO in TAMs at stroma of human tumors in situ.  
Experimental studies indicate that the IDO proteins are selectively high expressed by Mφ in 
several types of human tumors, including HCC (Zhao Q, et al. J Immunol. doi: 
10.4049/jimmunol.1100164). However, exposure to hepatoma cell culture supernatants did not 
elicit the IDO expression in monocytes/Mφs, which suggests that additional factors within the 
tumor milieu are required for inducing IDO expression in tumor Mφs. CD69 is an 
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immunoregulatory molecule expressed by early activated leukocytes at sites of chronic 
inflammation and CD69+ T cells have been found to promote human tumor progression [80, 
81]. Upon encountering autologous CD69+ T cells, tumor Mφs acquired capabilities to produce 
greatly higher amount of IDO protein. The T cells isolated from the HCC tissues expressed 
significant CD69 molecules than those on paired circulating and non-tumor-infiltrating T cells; 
and these tumor-derived CD69+ T cells could induce considerable IDO in monocytes. 
Interestingly, the tumor-associated monocytes/Mφ isolated from HCC tissues or generated by 
in vitro culture effectively activated circulating T cells to express CD69. IL-12 derived from 
tumor Mφ was required for early T cell activation and subsequent IDO expression (Zhao Q, et 
al. J Immunol. doi: 10.4049/jimmunol.1100164). Consistent with this, another recent study has 
shown that intratumoral delivery of exogenous IL-12 could elicit an IFN-Ǆ-dependent IDO 
counter-regulation in mouse model [82]. Moreover, the conditioned medium form IDO+ Mφ 
effectively suppressed T cell responses in vitro; an effect which could be reversed by adding 
extrinsic IDO substrate tryptophan or by pre-treating Mφs with an IDO-specific inhibitor 1-
MT. Such an active induction of immune-tolerance should be considered for the rational 
design of effective immune-based anti-cancer therapies. 
4.5 Increased intratumoral Treg cells are related to intratumoral Mφs and poor 
prognosis in HCC patients 
Treg cell-mediated immunosuppression is a crucial strategy of tumor immune evasion and a 
main obstacle for successful cancer immunotherapy [12]. Several recent studies have 
demonstrated that FoxP3+ Treg cells with immunosuppressive properties were concentrated 
within HCC tumors and that the intratumoral prevalence of FoxP3+ Treg cells was 
associated with disease progression and poor prognosis [10, 11]. However, the source of 
Treg cells in HCC is still unclear. By analyzing the association between the densities of Treg 
cells and Mφs in HCC tissue, Zhou et al observed that the elevated intratumoral FoxP3+ 
Treg population was correlated with high-intratumoral Mφ density in HCC patients [26]. 
Depletion of liver Mφs thus decreased the frequency of liver FoxP3+ Treg cells in hepatoma-
bearing mice. Additionally, Mφs exposed to TSNs from hepatoma-derived cell lines 
augmented the FoxP3+ Treg population, partially via IL-10. However, in the absence of Mφs, 
culture supernatants derived from hepatoma cells could not increase the percentage of 
FoxP3+ Treg cells upon anti-CD3/CD28 stimulation. These data indicated that HCC-
associated immunosuppressive Mφs can increase the intratumoral FoxP3+ Treg population. 
Cross talks between monocytes/Mφs and other stroma cells are summarized in Figure 3. 
Notably, the regulatory mechanisms of monocytes/Mφs are less well understood in human 
HCC. Besides interacting with TH17, TC17, Treg, and CD69+ T cells, tumor-associated 
monocytes/Mφs also secrete molecules (eg, TGF-ǃ, osteopontin), which directly induced 
epithelial-mesenchymal transition or transformation (EMT) of cancer cells [83]. Moreover, 
one of our latest finding indicated that monocytes/Mφs isolated from human HCC tissues 
induced NK cell dysfunction via a 2B4/CD48 interaction (Wu et al. Unpublished data). In 
addition, although not directly related to HCC, tumor-infiltrating Treg cells can trigger 
production of IL-10 by Mφs, which in turn stimulates such cells to express B7-H4 in an 
autocrine manner and renders them immunosuppressive via the B7-H4 molecules [84]. 
Therefore, manipulating the involved molecules may open new avenues for developing 
novel immune-based therapies to enhance antitumor immunity in human cancer. 
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Fig. 3. Map of Cross talks between monocytes/Mφs and other immune cells in distinct 
niches of HCC.  
5. Summary 
Much research has been focused on tumor-mediated immunosuppression over the past 
decade. However, in spite of the generalized immunosuppressive status in cancer patients, 
many malignancies arise at sites of chronic inflammation, and inflammatory mediators are 
often produced in tumors [85, 86]. Human HCC tissues can be anatomically classified into 
areas of intratumoral and peritumoral stroma, each with distinct compositions and 
functional properties [20, 21, 54, 55]. Intratumoral environments of HCC usually contain 
abundant immunosuppressive molecules and cells to inhibit the T cell responses and create 
conditions that are conducive to tumor growth [20, 26]. In contrast, the peritumoral stromal 
areas of HCC contain a significant amount of leukocyte infiltrate, which are thereby situated 
close to the advancing edge of a tumor [21, 54]. Monocytes/Mφs represent an abundant 
population of APCs in HCC. Soluble factors derived from hepatoma cells can alter the 
normal developmental process of Mφs that is intended to dynamically regulate monocyte 
activation at distinct sites [20]. Hepatoma-activated monocytes in the peritumoral stroma 
induce sequential expansion of memory TH17 and TC17 cells and infiltration of neutrophils 
to promote inflammation and angiogenesis at invading tumor edge [54, 55]. Of note, these 
activated monocytes also express high level of B7-H1 to inhibit tumor-specific T cell 
immunity [21], and in that way repurpose the inflammatory response away from anti-tumor 
immunity (the sword) and towards tissue remodeling and pro-angiogenic pathways (a 
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plowshare). Furthermore, interactions between suppressive Mφs and T cells in the cancer 
nest of HCC lead to Mφ IDO expression and Treg cell expansion [26]. Thus, it is not 
inflammation per se but inflammatory “context” that determines the ability of pro-
inflammatory factors to facilitate or prevent tumor growth. Studying the mechanisms that 
can selectively modulate the functional activities of monocytes/Mφs might provide a novel 
strategy for anticancer therapy. 
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